Nexalis Therapeutics (ASX:NX1) Enters Trading Halt Pending Debt Funding Update

Aditi Sarkar

22 May 2026 02:21 PM AEST

Nexalis Therapeutics (ASX:NX1) Enters Trading Halt Pending Debt Funding Update

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ASX Compliance has granted a Trading halt for Nexalis Therapeutics Limited at the Company’s request, with the halt notice dated 22 May 2026.
The trading halt is pending the release of an announcement regarding Nexalis’ existing Debt funding Facility.
The halt will remain in place until the earlier of the commencement of normal trading on Tuesday 26 May 2026 or the release of the relevant announcement to the market.
The Company’s request was made in accordance with ASX Listing Rule 7.1, with supporting information provided under ASX Listing Rule 17.1.
Nexalis states that the trading halt is necessary to assist the Company in managing its continuous disclosure obligations as it expects to make an announcement to the market regarding the debt funding facility.
The Company expects to make the announcement before the commencement of normal trading on Tuesday 26 May 2026.
The request was approved by the board of Nexalis Therapeutics Ltd and signed by James Barrie, Company Secretary.

Nexalis Therapeutics Limited (ASX:NX1) has entered a trading halt on 22 May 2026, pending the release of a market announcement regarding the Company’s existing debt funding facility.

ASX Compliance issued the trading halt notice at the request of Nexalis. According to the ASX release, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday 26 May 2026 or the release of the announcement to the market.

The request, signed by Company Secretary James Barrie, was made under ASX Listing Rule 7.1 with supporting information provided under ASX Listing Rule 17.1, and was approved by the board of Nexalis Therapeutics Ltd.

What the company announced

On 22 May 2026 ASX Compliance issued a market announcement confirming that trading in the securities of Nexalis Therapeutics Ltd (ASX: NX1) would be halted at the request of NX1, pending the release of an announcement by NX1.

The notice states that, unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday 26 May 2026 or the release of the announcement to the market.

The Company’s underlying request for the trading halt, addressed to Melissa Kostopoulos, Senior Adviser – ASX Supervision at the Australian Securities Exchange, requested the immediate trading halt of the Company’s securities in accordance with ASX Listing Rule 7.1.

The trading halt is requested pending an announcement to the market regarding the Company’s existing debt funding facility, referred to in the request as the ‘Purpose’.

In accordance with ASX Listing Rule 17.1, the Company provided the following information: the halt is necessary to assist the Company in managing its continuous disclosure obligations as it expects to make an announcement to the market in relation to the Purpose; the Company requests that the halt remain in place until the earlier of commencement of normal trading on Tuesday 26 May 2026 or release of the announcement; the Company expects to make the announcement regarding the Purpose to the market before the commencement of normal trading on Tuesday 26 May 2026; and the Company is not aware of any reason why the trading halt should not be granted, or of any other information necessary to inform the market about the trading halt.

The request was approved by the board of Nexalis Therapeutics Ltd and signed by James Barrie, Company Secretary. Investor enquiries are directed to +61 3 9070 1221 or [email protected].

Key numbers from the announcement

Trading halt notices are procedural in nature and contain limited numerical detail. The structural and timing references below are drawn directly from the ASX market announcement and the Company’s trading halt request.

Announcement date: 22 May 2026.
Halt requestor: Nexalis Therapeutics Limited.
Halt grantor: ASX Compliance.
ASX Listing Rule cited for the request: 7.1.
ASX Listing Rule cited for the supporting information: 17.1.
Latest possible end of halt: commencement of normal trading on Tuesday 26 May 2026, unless ASX decides otherwise.
Alternative end of halt: release of the relevant announcement to the market.
Expected timing of the announcement: before the commencement of normal trading on Tuesday 26 May 2026.
Subject matter of the upcoming announcement: the Company’s existing debt funding facility.
Request signed by: James Barrie, Company Secretary.
Request directed to: Melissa Kostopoulos, Senior Adviser – ASX Supervision.

Trading halts and the ASX continuous disclosure framework

Trading halts are a standard tool under the ASX Listing Rules used by listed entities to manage continuous disclosure obligations when material information is being prepared for release to the market. They allow the company time to finalise the announcement while ensuring that trading does not occur on the basis of incomplete information.

In this case, Nexalis Therapeutics has requested a halt specifically in connection with an announcement regarding its existing debt funding facility. The notice does not disclose the substance of the upcoming announcement; it simply identifies the subject matter and the expected timing.

The cited rules — ASX Listing Rule 7.1 (which the Company referenced in its halt request) and ASX Listing Rule 17.1 (which sets out the information requirements for a halt) — together provide the procedural framework for this process. The Company expressly confirms it is not aware of any reason why the trading halt should not be granted.

Under standard ASX practice, trading halts of this kind generally remain in place until the company releases the relevant announcement or, in the absence of an announcement, until trading resumes on the second Business day after the halt is granted. In this instance, the resumption is scheduled for the commencement of normal trading on Tuesday 26 May 2026.

The release does not provide any commentary on the underlying terms or status of the Company’s debt funding facility. Investors will need to await the substantive announcement for further detail.

Management commentary

The trading halt notice and the underlying request are procedural documents and do not contain a separate management Quotation. The request was approved by the board of Nexalis Therapeutics Ltd and signed by James Barrie, Company Secretary.

Why this ASX announcement matters

Trading halts are routine procedural events on the ASX, particularly where listed entities are finalising market-sensitive disclosures. The fact that Nexalis is seeking a halt to manage its continuous disclosure obligations indicates that an announcement is being prepared.

For NX1 shareholders, the key timing markers are clear: the halt remains in place until the earlier of normal trading on Tuesday 26 May 2026 or the release of the announcement. This provides a defined window for the next material update.

Because the subject matter relates to the Company’s existing debt funding facility, the upcoming announcement may be relevant to assessments of Nexalis’ financing arrangements. The specific terms and implications, however, will only be determinable when the announcement is released.

The Company’s confirmation that it is not aware of any reason why the trading halt should not be granted, together with board approval of the request, is consistent with standard ASX disclosure expectations.

Investors and analysts should focus on the substantive announcement when it is released, rather than seeking to infer details from the halt request itself, which by design contains only limited information.

Investor implications

Investors are unable to trade Nexalis Therapeutics securities while the trading halt is in place. The halt may end either when the relevant announcement is released or on the commencement of normal trading on Tuesday 26 May 2026, whichever is earlier.

Any decision-making regarding NX1 securities should consider that material information regarding the Company’s debt funding facility is expected to be released within this window. Until that information is in the public domain, Market Participants should be cautious about making assumptions about the content of the announcement.

The trading halt does not, in itself, indicate any particular outcome regarding the debt funding facility. It is a procedural mechanism to manage the orderly release of information under the ASX Listing Rules.

Investors holding open trading instructions should consider how their orders may be affected by the halt and any subsequent reopening of trading once the announcement is released.

Risks and uncertainties

Disclosure risk: the substance of the upcoming announcement has not been disclosed. The halt request explicitly states only the subject matter (the existing debt funding facility) and the timing window.

Trading risk: investors cannot trade NX1 securities while the halt is in place. On resumption, market reaction to the substantive announcement could result in price Volatility.

Outcome risk: the announcement may relate to a variety of matters concerning the existing debt funding facility. Investors should not infer from this notice any particular outcome.

Timing risk: while the Company expects to make the announcement before the commencement of normal trading on Tuesday 26 May 2026, the timing remains subject to its continuous disclosure processes.

Forward-looking statement risk: any forward-looking statements that may be made in the subsequent announcement should be assessed in light of the standard risks applicable to such statements, including risks specific to the Company’s financing arrangements.

What investors should watch next

The substantive ASX announcement from Nexalis Therapeutics regarding its existing debt funding facility, expected before the commencement of normal trading on Tuesday 26 May 2026.
Any further communication from ASX Compliance regarding the trading halt or its expected end.
Standard market reopening on Tuesday 26 May 2026 if the announcement has been released and the halt lifted prior to that date.
Any related corporate disclosures from Nexalis Therapeutics regarding Capital Structure, financing arrangements or the use of any proceeds.
Subsequent quarterly or half-year financial reporting that may provide additional context for the debt funding facility outcome.

FAQs

Q: What did Nexalis Therapeutics (ASX: NX1) announce on 22 May 2026?

A: ASX Compliance issued a market announcement confirming that trading in NX1 securities is halted at the Company’s request, pending an announcement to the market regarding Nexalis’ existing debt funding facility.

Q: How long is the trading halt expected to last?

A: The trading halt will remain in place until the earlier of the commencement of normal trading on Tuesday 26 May 2026 or the release of the relevant announcement to the market, unless ASX decides otherwise.

Q: Why has the trading halt been requested?

A: The Company states that the halt is necessary to assist it in managing its continuous disclosure obligations as it expects to make an announcement to the market regarding its existing debt funding facility. The request was made in accordance with ASX Listing Rule 7.1, with supporting information provided under ASX Listing Rule 17.1.

Q: Who approved and signed the trading halt request?

A: The request was approved by the board of Nexalis Therapeutics Ltd and signed by James Barrie, Company Secretary, and was addressed to Melissa Kostopoulos, Senior Adviser – ASX Supervision at the Australian Securities Exchange.

Q: What should investors do now?

A: Trading in NX1 securities is paused while the halt is in place. Investors should await the substantive ASX announcement from Nexalis regarding its existing debt funding facility, expected before the commencement of normal trading on Tuesday 26 May 2026, and consider that information in any decision-making, including with the assistance of independent professional advice where appropriate.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.